12:00 AM
 | 
Jan 08, 2001
 |  BioCentury  |  Strategy

Biovail's brand play

Biovail Corp.'s $409.5 million purchase of North American rights to Aventis Pharmaceuticals' line of Cardizem diltiazem calcium channel blockers may look like a lot of money to spend on a group of branded generic products with declining sales. But for Biovail, the acquisition is less about absolute sales than it is about the acquisition of a well known brand name under which the company plans to launch its upcoming cardiovascular products.

Biovail (BVF; TSE:BVF, Toronto, Ontario), which was planning to launch a once-daily...

Read the full 408 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >